What is wrong with the 30-year-old practice of scalp cooling for the prevention of chemotherapy-induced hair loss?

@article{Breed2004WhatIW,
  title={What is wrong with the 30-year-old practice of scalp cooling for the prevention of chemotherapy-induced hair loss?},
  author={Wim P. M. Breed},
  journal={Supportive Care in Cancer},
  year={2004},
  volume={12},
  pages={3-5}
}
  • W. Breed
  • Published 2004
  • Medicine
  • Supportive Care in Cancer
Since about 1970 scalp cooling has been used to prevent chemotherapy-induced hair loss, one of the most common and emotionally distressing side effects of cancer therapy. Generally accepted opinions, uncertainty and controversy, topics to study and recommendations for improving the results of scalp cooling are the subjects of this article which was also presented at the MASCC Symposium, June 2003, Berlin. 

Scalp Cooling: The prevention of chemotherapy‐induced alopecia

  • A. Katz
  • Medicine
    Clinical journal of oncology nursing
  • 2017
The use of scalp cooling devices requires additional chair time that may affect patient flow in chemotherapy units, and the impact on nursing care provision is presented.

Hair loss as a consequence of cancer chemotherapy – physical methods of prevention. A review of the literature

Electrotrichogenesis, or the use of a specific pulsed electric field, has shown promising results in preventing chemotherapyinduced hair loss without attributable side effects.

The prevention of chemotherapy-induced alopecia

S usan, a patient who will undergo chemotherapy for treatment of ovarian cancer, requests a meeting with the unit manager to discuss her wish to use a scalp cooling device to prevent hair loss from

Scalp cooling to prevent or reduce chemotherapy-induced alopecia

The amassing evidence regarding scalp cooling for prevention of chemotherapy-induced alopecia has demonstrated that this is an effective, safe and well tolerated intervention which may provide an improved quality of life for patients undergoing chemotherapy for neoplastic disease.

Scalp cooling alopecia prevention trial (SCALP).

Success rates are variable, but scalp cooling appears to be effective in preventing chemotherapy-induced alopecia especially in more recent studies.

Numerical Simulation of Scalp Cooling to Prevent Chemotherapy-Induced Alopecia.

The thickness of the hair layer is of great importance for both perfusion and temperature, so reducing the thickness resulted in a decrease in temperature, and decreased relative perfusion, indicating that chances of preserving hair are higher.

Skin toxicity of anti‐cancer therapy

The various cutaneous reactions to chemotherapy and their most common causative agents, the adverse events of radiation therapy, as well as the characteristic skin changes under treatment with new molecular‐driven targeted agents are reviewed.

Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment

In this first comparison published to date, both PAX and CC offer efficacious protection against hair loss, in particular when docetaxel is administered in a 3-weekly interval.

Determination of the most effective cooling temperature for the prevention of chemotherapy-induced alopecia.

A pre-set temperature of 3°C tended to be the most efficient in achieving a hair follicle temperature of <22°C, although a higher incidence of side effects was associated with a lower temperature level.

Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial

Among women with stage I to II breast cancer receiving chemotherapy with a taxane, anthracycline, or both, those who underwent scalp cooling were significantly more likely to have less than 50% hair loss after the fourth chemotherapy cycle compared with those who received no scalp cooling.